Search Results
Meet the Researcher: Maria Figueroa, MD
Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancer, and what inspires their efforts to find better treatments and cures. Dr. Maria “Ken” Figueroa, Associate Professor and Co-Leader of the Cancer Epigenetics Research Program at Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, is focused on an exciting area of research called epigenetics.
Ivosidenib
Ivosidenib is FDA approved for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test in:
Brexucabtagene autoleucel
Brexucabtagene autoleucel is FDA approved for the treatment of
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Rituximab and hyaluronidase human
Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
Burlington Stores Raise $3.3 Million to Help Fight Blood Cancer
Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) Light The Night campaign’s 16th consecutive year of partnership in the fight against blood cancers was a big success. As LLS’s #1 National Corporate Partner and Honored Friend, Burlington Stores raised $3.3 million to fund blood cancer research and help patients access lifesaving treatments and cures.
LLS “FACEBOOK LIVE” INSPIRES THE NEXT GENERATION OF SCIENTISTS
As schools and education communities across the country have had to adjust to a new way of learning online, The Leukemia & Lymphoma Society’s Pennies for Patients program (www.penniesforpatients.org), a science-based service-learning program for schools, has shifted in-person school learning events to a virtual semi-weekly STEM+ curriculum program to inspire the next generation of scientists and doctors.
Nutrition Advice from a Dietitian & Blood Cancer Survivor
76-year-old Barbara Borrell is a woman who wears many hats – a 50+ year registered dietitian, nutrition consultant and educator, cancer advocate, volunteer with The Leukemia & Lymphoma Society, and a blood cancer survivor who has battled not one, not two, but three types of blood cancer.
Filgrastim
Filgrastim is FDA approved to
Sargramostim
Sargramostim is FDA approved
Gilteritinib
Gilteritinib is a indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Tisagenlecleucel
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of
LLS and Burlington Celebrate 20 years of Fighting Blood Cancer Together!
The Leukemia & Lymphoma Society (LLS) and Burlington Stores are marking two decades of an incredible partnership this year. With Burlington’s help, LLS has been able to provide free information, education, and 1:1 support for hundreds of thousands of blood cancer patients. And we’re still going strong. Continuing the momentum, Burlington is committed to helping support lifesaving research for the LLS Children’s Initiative.